Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter February 23, 2011

Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease

  • David Prvulovic and Harald Hampel EMAIL logo


A growing body of evidence suggests that Alzheimer's disease (AD) is a multifactorial disease resulting in the well-known, common neuropathological pathway characterized by extracellular fibrillar β amyloid (Aβ) deposits in the brain, intracellular neurofibrillary tangles (NFT) and neuronal as well as axonal degeneration. While fairly accurate, the clinical diagnosis of probable AD based on standard diagnostic criteria does not take into account the long preclinical and prodromal course of AD. AD-related pathophysiological changes can occur many years and even decades before the appearance of clinical dementia syndrome. Biomarkers that are related to the pathophysiology of AD may thus help detect the preclinical stages of disease, and improve early and differential diagnosis. Here, we provide an overview of current literature on the core AD biomarkers, Aβ and phosphor-tau (p-tau), on different methods and modalities of assessing them [e.g., cerebrospinal fluid (CSF) analysis and PET imaging], and on their diagnostic and predictive value in preclinical and clinical stages of AD.

Corresponding author: Harald Hampel, Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University of Frankfurt, Heinrich-Hoffmann-Str. 10, 60528 Frankfurt, Germany Phone: +49 (0)69 6301 6373, Fax: +49 (0)69 6301 87303

Received: 2010-11-11
Accepted: 2011;-1-19
Published Online: 2011-02-23
Published in Print: 2011-03-01

©2011 by Walter de Gruyter Berlin New York

Downloaded on 11.12.2023 from
Scroll to top button